# Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants

> **NCT06895993** · PHASE1 · COMPLETED · sponsor: **Sichuan Huiyu Pharmaceutical Co., Ltd** · enrollment: 84 (actual)

## Conditions studied

- Healthy Adult

## Interventions

- **DRUG:** Ferric Carboxymaltose Injection
- **DRUG:** Ferric Carboxymaltose Injection [Injectafer®]

## Key facts

- **NCT ID:** NCT06895993
- **Lead sponsor:** Sichuan Huiyu Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-07
- **Primary completion:** 2025-05-08
- **Final completion:** 2025-05-08
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-05-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06895993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06895993, "Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06895993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*